/dq/media/agency_attachments/UPxQAOdkwhCk8EYzqyvs.png)
/dq/media/member_avatars/AYMcEOCg0Hat7pNZP430.jpeg )
Follow Us/dq/media/media_files/Eda57v19pbAWJtQc6Cbw.png)
BioE3 Policy
In a bold stride towards establishing India as a global biotech powerhouse, the Indian government has rolled out the ambitious BioE3 (Biotechnology for Economy, Employment, and Environment) Policy. The policy was announced by Union Minister Dr. Jitendra Singh and is expected to catapult India into a leadership position on the world stage, marking a significant milestone in the nation’s journey towards economic, environmental, and technological advancement.
India’s Bioeconomy Soars
Over the past decade, India’s bioeconomy has experienced an extraordinary ascent, surging from $10 billion in 2014 to over $130 billion in 2024. With projections to hit $300 billion by 2030, the country is poised to redefine the global biotech landscape. Dr. Jitendra Singh lauded Prime Minister Narendra Modi’s leadership, crediting him with championing this biotech revolution that promises to bolster the economy, spark innovation, create jobs, and advance environmental commitments.
A Visionary Shift in Manufacturing
The BioE3 Policy represents a pivotal shift from traditional consumptive practices to high-performance, regenerative bio-manufacturing. Dr. Singh emphasized that this transition is not just a step forward but a leap toward a cleaner, greener, and more prosperous India. The policy is designed to tackle global challenges head-on, from climate change to the depletion of non-renewable resources, by fostering a sustainable bio-based economy.
Experts Opinion
Dr. Viswanadham Duppatla, VP-Biomanufacturing, IKP, said, "The BioE3 Policy will be a major boost for India's biopharma sector, positioning us as a strong alternative to China for biologics and personalized medicine, especially with the China Plus One (C+1) strategy gaining traction among global companies. The recent decision by the DGCI to waive clinical trials for drugs already approved in countries like the US, UK, EU, Japan, Australia, and Canada further strengthens India's standing as a prime destination for advanced therapeutics and manufacturing. Coupled with the Production Linked Incentive (PLI) scheme and the fact that over 70 biosimilars are going off-patent between 2024 and 2028, we are in a prime position to meet global medical needs. India's biopharmaceutical landscape is brimming with potential. By seizing these opportunities, embracing innovation, and streamlining regulations, we can make a significant impact on global healthcare."
Dr. Faith Jiwakhan, Co-founder and CCO at Aether Biomedical, said, "As the founder of a medical device company, I am thrilled by the Union Cabinet's approval of the BioE3 Policy. This forward-thinking initiative is a game-changer for the biotech sector, particularly for companies that rely on cutting-edge biotechnology. The focus on precision biotherapeutics and high-performance biomanufacturing will undoubtedly accelerate innovation and bring us closer to creating more effective and affordable healthcare solutions. The commitment to fostering collaboration and expanding R&D capabilities is exactly what our industry needs to thrive in a competitive global market.
Additionally, I believe they should put special focus on increasing the skill set of professionals so that the respective companies can build global standard products and bring positive changes in the lives of people from every strata of the society."
Key Drivers of Change
At the heart of the BioE3 Policy are four critical objectives:
- Promoting a shift from chemical-based industries to sustainable bio-based models
- Fostering a Circular Bioeconomy
- Achieving net-zero carbon emissions
- Expanding the development of bio-based products.
The policy also strongly emphasizes ethical biosafety considerations and aligns with international regulatory standards, positioning India as a responsible leader in the global biotech sector.
Catalyzing Innovation and Employment
Dr. Singh highlighted the policy’s potential to drive innovation across diverse sectors, including bio-based chemicals, smart proteins, precision biotherapeutics, and climate-resilient agriculture. The establishment of cutting-edge biomanufacturing facilities, bio-foundry clusters, and Bio-AI hubs is expected to catalyze this innovation, bridging the gap between laboratory-scale research and commercial-scale manufacturing.
These hubs will be instrumental in the large-scale production of advanced products such as mRNA-based vaccines and novel proteins. By integrating artificial intelligence with biological data, Bio-AI hubs will pave the way for groundbreaking developments in gene therapies and food processing solutions.
The BioE3 Policy is also a powerful engine for job creation, particularly in India’s tier-II and tier-III cities. By setting up biomanufacturing hubs that leverage local biomass sources, the policy aims to spur economic development in these regions, creating substantial employment opportunities and contributing to the broader goal of a ‘Viksit Bharat’.
Read More:
Semicon growth in India: Impetus and interventions
India Races Towards AI Future: Huge Potential, Challenges Remain
Indian Government Issues Clarification on Old and New Tax Regime